CARDIOVASCULAR JOURNAL OF AFRICA • Volume 33, No 2, March/April 2022 AFRICA 59 48. Abujbara M, Batieha A, Khader Y, Jaddou H, El-Khateeb M, Ajlouni K. The prevalence of dyslipidemia among Jordanians. J Lipids 2018; 2018: 6298739. 49. Feng YM, Zhao D, Zhang N, Yu CG, Zhang Q, Thijs L, et al. Insulin resistance in relation to lipids and inflammation in type-2 diabetic patients and non-diabetic people. PLoS One 2016; 11(4): e0153171. 50. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357(21): 2109–2122. 51. Rader DJ, deGoma EM. Approach to the patient with extremely low HDL-cholesterol. Clin Endocrinol Metab 2012; 97(10): 3399–3407. 52. Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005; 16(2): 139–145. 53. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58(3): 342–374. 54. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014; 20(2): 193–203.
RkJQdWJsaXNoZXIy NDIzNzc=